Involvement of different nuclear hormone receptors in butyrate-mediated inhibition of inducible NFκB signalling

Molecular Immunology

Volumn 44, Issue 15, 2007, Pages 3625-3632

  Schwab, Markus ^a   Reynders, Veerle ^a   Loitsch, Stefan ^a   Steinhilber, Dieter ^a   Stein, Jürgen ^a   Schröder, Oliver ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Butyrate; HT 29; Inflammation; LPS; NF B; PPAR ; TNF ; VDR

Indexed keywords

BUTYRIC ACID; DIMER; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN P50; RECEPTOR BLOCKING AGENT; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; VITAMIN D RECEPTOR ANTAGONIST; ZK 191732;

ARTICLE; CELL CULTURE; CELL STRAIN HT29; CONTROLLED STUDY; CULTURE MEDIUM; CYTOSOL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; UPREGULATION;

BUTYRATES; CYTOSOL; DIMERIZATION; DNA; HT29 CELLS; HUMANS; I-KAPPA B PROTEINS; LIPOPOLYSACCHARIDES; NF-KAPPA B P50 SUBUNIT; PPAR GAMMA; RECEPTORS, CALCITRIOL; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 34249341731     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2007.04.010     Document Type: Article

References (46)

1. Akira S., and Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 4 (2004) 499-511
2. Baeuerle P.A. IkappaB-NF-kappaB structures: at the interface of inflammation control. Cell 95 (1998) 729-731
3. Baeuerle P.A., and Baltimore D. NF-kappa B: ten years after. Cell 87 (1996) 13-20
4. Ben-Neriah Y. Regulatory functions of ubiquitination in the immune system. Nat. Immunol. 3 (2002) 20-26
5. Brynskov J., Nielsen O.H., Ahnfelt-Ronne I., and Bendtzen K. Cytokines (immunoinflammatory hormones) and their natural regulation in inflammatory bowel disease (Crohn's disease and ulcerative colitis): a review. Dig. Dis. 12 (1994) 290-304
6. Cario E., and Podolsky D.K. Intestinal epithelial TOLLerance versus inTOLLerance of commensals. Mol. Immunol. 42 (2005) 887-893
7. Chakravortty D., Koide N., Kato Y., Sugiyama T., Mu M.M., Yoshida T., and Yokochi T. The inhibitory action of butyrate on lipopolysaccharide-induced nitric oxide production in RAW 264.7 murine macrophage cells. J. Endotoxin. Res. 6 (2000) 243-247
8. Daynes R.A., and Jones D.C. Emerging roles of PPARs in inflammation and immunity. Nat. Rev. Immunol. 2 (2002) 748-759
9. Desvergne B., and Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20 (1999) 649-688
10. Di Sabatino A., Morera R., Ciccocioppo R., Cazzola P., Gotti S., Tinozzi F.P., Tinozzi S., and Corazza G.R. Oral butyrate for mildly to moderately active Crohn's disease. Aliment Pharmacol. Ther. 22 (2005) 789-794
11. Dubuquoy L., Dharancy S., Nutten S., Pettersson S., Auwerx J., and Desreumaux P. Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases. Lancet 360 (2002) 1410-1418
12. Dubuquoy L., Jansson E.A., Deeb S., Rakotobe S., Karoui M., Colombel J.F., Auwerx J., Pettersson S., and Desreumaux P. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology 124 (2003) 1265-1276
13. Dubuquoy L., Rousseaux C., Thuru X., Peyrin-Biroulet L., Romano O., Chavatte P., Chamaillard M., and Desreumaux P. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 55 (2006) 1341-1349
14. Eun C.S., Han D.S., Lee S.H., Paik C.H., Chung Y.W., Lee J., and Hahm J.S. Attenuation of colonic inflammation by PPARgamma in intestinal epithelial cells: effect on Toll-like receptor pathway. Dig. Dis. Sci. 51 (2006) 693-697
15. Gaschott T., and Stein J. Short-chain fatty acids and colon cancer cells: the vitamin D receptor-butyrate connection. Recent Results Cancer Res. 164 (2003) 247-257
16. Gaschott T., Werz O., Steinmeyer A., Steinhilber D., and Stein J. Butyrate-induced differentiation of Caco-2 cells is mediated by vitamin D receptor. Biochem. Biophys. Res. Commun. 288 (2001) 690-696
17. Ghosh S., and Karin M. Missing pieces in the NF-kappaB puzzle. Cell 109 Suppl. (2002) S81-S96
18. Giuliano A.R., Franceschi R.T., and Wood R.J. Characterization of the vitamin D receptor from the Caco-2 human colon carcinoma cell line: effect of cellular differentiation. Arch. Biochem. Biophys. 285 (1991) 261-269
19. Gurnell M., Wentworth J.M., Agostini M., Adams M., Collingwood T.N., Provenzano C., Browne P.O., Rajanayagam O., Burris T.P., Schwabe J.W., Lazar M.A., and Chatterjee V.K. A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis. J. Biol. Chem. 275 (2000) 5754-5759
20. Harant H., Wolff B., and Lindley I.J. 1Alpha 25-dihydroxyvitamin D3 decreases DNA binding of nuclear factor-kappaB in human fibroblasts. FEBS Lett. 436 (1998) 329-334
21. Inan M.S., Rasoulpour R.J., Yin L., Hubbard A.K., Rosenberg D.W., and Giardina C. The luminal short-chain fatty acid butyrate modulates NF-kappaB activity in a human colonic epithelial cell line. Gastroenterology 118 (2000) 724-734
22. Kaplan J.M., Cook J.A., Hake P.W., O'Connor M., Burroughs T.J., and Zingarelli B. 15-Deoxy-delta(12,14)-prostaglandin J(2) (15D-PGJ(2)), a peroxisome proliferator activated receptor gamma ligand, reduces tissue leukosequestration and mortality in endotoxic shock. Shock 24 (2005) 59-65
23. Karin M., and Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu. Rev. Immunol. 18 (2000) 621-663
24. Klurfeld D.M. Nutritional regulation of gastrointestinal growth. Front. Biosci. 4 (1999) D299-D302
25. Lee K.S., Park S.J., Kim S.R., Min K.H., Jin S.M., Lee H.K., and Lee Y.C. Modulation of airway remodeling and airway inflammation by peroxisome proliferator-activated receptor gamma in a murine model of toluene diisocyanate-induced asthma. J. Immunol. 177 (2006) 5248-5257
26. Luhrs H., Kudlich T., Neumann M., Schauber J., Melcher R., Gostner A., Scheppach W., and Menzel T.P. Butyrate-enhanced TNFalpha-induced apoptosis is associated with inhibition of NF-kappaB. Anticancer Res. 22 (2002) 1561-1568
27. Nagpal S., Na S., and Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr. Rev. 26 (2005) 662-687
28. Ogawa H., Rafiee P., Fisher P.J., Johnson N.A., Otterson M.F., and Binion D.G. Butyrate modulates gene and protein expression in human intestinal endothelial cells. Biochem. Biophys. Res. Commun. 309 (2003) 512-519
29. Orange J.S., and Geha R.S. Finding NEMO: genetic disorders of NF-[kappa]B activation. J. Clin. Invest. 112 (2003) 983-985
30. Place R.F., Noonan E.J., and Giardina C. HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha. Biochem. Pharmacol. 70 (2005) 394-406
31. Quivy V., and Van Lint C. Regulation at multiple levels of NF-kappaB-mediated transactivation by protein acetylation. Biochem. Pharmacol. 68 (2004) 1221-1229
32. Sartor R.B. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am. J. Gastroenterol. 92 (1997) 5S-11S
33. Schauber J., Iffland K., Frisch S., Kudlich T., Schmausser B., Eck M., Menzel T., Gostner A., Luhrs H., and Scheppach W. Histone-deacetylase inhibitors induce the cathelicidin LL-37 in gastrointestinal cells. Mol. Immunol. 41 (2004) 847-854
34. Schutze S., Potthoff K., Machleidt T., Berkovic D., Wiegmann K., and Kronke M. TNF activates NF-kappa B by phosphatidylcholine-specific phospholipase C-induced "acidic" sphingomyelin breakdown. Cell 71 (1992) 765-776
35. Schwab M., Reynders V., Shastri Y., Loitsch S., Stein J., and Schroder O. Role of nuclear hormone receptors in butyrate-mediated up-regulation of the antimicrobial peptide cathelicidin in epithelial colorectal cells. Mol. Immunol. 44 (2007) 2117-2124
36. Schwab M., Reynders V., Ulrich S., Zahn N., Stein J., and Schroder O. PPARgamma is a key target of butyrate-induced caspase-3 activation in the colorectal cancer cell line Caco-2. Apoptosis 11 (2006) 1801-1811
37. Segaert S., and Bouillon R. Vitamin D and regulation of gene expression. Curr. Opin. Clin. Nutr. Metab. Care 1 (1998) 347-354
38. Segain J.P., Raingeard de la Bletiere D., Bourreille A., Leray V., Gervois N., Rosales C., Ferrier L., Bonnet C., Blottiere H.M., and Galmiche J.P. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut 47 (2000) 397-403
39. Siebenlist U., Franzoso G., and Brown K. Structure, regulation and function of NF-kappa B. Annu. Rev. Cell Biol. 10 (1994) 405-455
40. Stio M., Martinesi M., Bruni S., Treves C., Mathieu C., Verstuyf A., d'Albasio G., Bagnoli S., and Bonanomi A.G. The Vitamin D analogue TX 527 blocks NF-kappaB activation in peripheral blood mononuclear cells of patients with Crohn's disease. J. Steroid Biochem. Mol. Biol. 103 (2007) 51-60
41. Sun J., Kong J., Duan Y., Szeto F.L., Liao A., Madara J.L., and Li Y.C. Increased NF-kappaB activity in fibroblasts lacking the vitamin D receptor. Am. J. Physiol. Endocrinol. Metab. 291 (2006) E315-E322
42. Tirona R.G., and Kim R.B. Nuclear receptors and drug disposition gene regulation. J. Pharm. Sci. 94 (2005) 1169-1186
43. Wachtershauser A., Loitsch S.M., and Stein J. PPAR-gamma is selectively upregulated in Caco-2 cells by butyrate. Biochem. Biophys. Res. Commun. 272 (2000) 380-385
44. Wachtershauser A., and Stein J. Rationale for the luminal provision of butyrate in intestinal diseases. Eur. J. Nutr. 39 (2000) 164-171
45. Yin L., Laevsky G., and Giardina C. Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity. J. Biol. Chem. 276 (2001) 44641-44646
46. Yu X.P., Bellido T., and Manolagas S.C. Down-regulation of NF-kappa B protein levels in activated human lymphocytes by 1,25-dihydroxyvitamin D3. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 10990-10994